|
|
| |
CRU Organization
Dean, Faculty of Tropical Medicine
Chief, Clinical Trial Project
Staffs
 |
|
|
|
| |
| |
|
|
| |
| |
CRU Organization 2006 > About VTC >
 |
|
| |
|
| |
Enrollment and retention rate of various projects conducted by VTC
|
|
Protocols |
Date of activation |
Total Enrolled |
% Expected Enrolled |
Total visit Retention (%) |
Total visits Expected |
gp120/alum, subtype B (phase I/II)
|
February 1995 - December 1996 |
33 |
100% |
693 (100) |
693 |
gp120/MF59, subtype E antigen alone or combined with B antigen (phase I/II)
|
1997-1999 |
370 |
100% |
783 (99.87) |
784 |
gp120/alum, combined subtype B (AIDSVAX  B/E) (phase I/II) |
January 1998 - August 1999 |
92 |
100% |
1,158 (96.82) |
1,196 |
gp120/alum, combined subtype B,E (AIDSVAX B/E) (phase I/II) |
March 1999 - 2003 |
2,500 |
100% |
35,041 (91.79) |
38,175 |
ALVAC-HIV rgp 120 B/E boost (phase I/II)
|
2000-2002 |
123
(VTC 62) |
100% |
587 (97.83) |
600 |
ALVAC-HIV rgp 120 B/E boost (phase III)
|
September 2003 - present |
6,963 |
On process Recruitment |
83.354 (89.19)* |
93.456* |
MRKAd5 HIV-1 gag vaccine (phase I)
|
November 2003 - present |
87
(VTC 29) |
100% |
471 (98.33)** |
479** |
Overall Protocols |
7 |
|
|
|
|
* recruitment is on process, data available as of May 31, 2005
** study is on going, data available as of May, 2005
<< Back |
|
|
|
|
|
|
